Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Proton pump inhibitors are drugs mainly used for prolong and profound reduction of stomach acid levels in individuals suffering from gastroesophageal reflux disease, hyperacidity and ulcers. Proton pump inhibitors (PPIs) have a unique mechanism of action as they are given in an inactive form which are lipophilic in nature and readily cross cell membranes into intracellular compartments like the parietal cell canaliculus with acidic environments, then the inactive drug is protonated and rearranged into its active form in acidic environments and irreversibly blocks the gastric proton pump of the gastric parietal cells.
The global proton pump inhibitors market is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% during the forecast period (2020-2027).
Figure 1. Global Proton Pump Inhibitors Market, by Market value (US$ Bn), by 2016-2027
The increasing prevalence of obesity in adults and adolescents is leading to various conditions related to gastroesophageal reflux disease such as Barret's esophagus (BE), esophageal erosions and esophageal adenocarcinoma. The US National Library of Medicine report published in 2017 stated that individuals with higher body mass index (BMI) have a higher risk of gastrointestinal diseases such as gastroesophageal reflux disease and can lead to esophageal erosions.
Moreover, increasing prevalence of gastrointestinal diseases such as duodenal ulcers, barrets esophagus, and non-erosive reflux disease (NERD) are the factors expected to drive the global proton pump inhibitor market growth. According to US National Library of Medicine report published in July 2020, more than 60% of individuals are suffering from non- erosive reflux disease (NERD) and 30% of people are suffering from barrets esophagus in the US.
Proton Pump Inhibitors Market Report Coverage
||Market Size in 2020:
||US$ 2.9 Bn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 3.5 Bn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of the Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Type: Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, Others.
- By Disease Indication: Ulcers, Gastroesophageal Reflux Disease, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others.
AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited
- The increasing prevalence of gastroesophageal reflux disease and ulcers such as peptic ulcers, duodenal ulcers
- The increasing presence of local/generic drug manufacturers
- Strong product pipeline, approval of new proton pump inhibitor drugs for treatment of gastroesophageal reflux disease GERD and ulcers
|Restraints & Challenges:
- Proton pump inhibitors lead to an increase in risk of Clostridium difficile infection of the colon
- Long term use of PPI may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.
Global Proton Pump Inhibitors Market – Impact of Coronavirus (COVID-19)
Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in more than 34,804,348 infected individuals worldwide as of 4th October 2020.
COVID-19 can affect tin three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. have been disrupted due to nationwide lockdowns. While countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another. Moreover, individuals using proton pump inhibitors medication for longer term duration are more prone towards getting infected by COVID-19 infections. According to the National Library of Medicine Report published in August 2020, use of proton pump inhibitors can increase risk of COVID-19. Moreover, individuals using proton pump inhibitors twice daily are more likely to get infected by COVID-19. These factors are restraining the growth of global proton pump inhibitor market. Therefore, COVID-19 pandemic has also hampered the global proton pump inhibitor market in negative way.
Figure 2. Global Proton Pump Inhibitors Market share (%), by Region, 2020
Among regions, the North America market is expected to witness significant growth owing to an increasing approvals of proton pump inhibitors products. For instance, in 2017, AstraZeneca plc/AB, a biopharmaceutical and pharmaceutical company, received the U.S. Food Drug and Administration’s approved for use of Nexium (esomeprazole magnesium), for treating gastroesophageal reflux disease in children in the age group of 1 to 11 for short term use.
The Europe proton pump inhibitor market is expected to exhibit significant growth during the forecast period owing to increasing focus of key players on obtaining approvals and on launching products. For instance, in April 2018, Perrigo Company plc and its partner, Dexcel Pharma Technologies, Ltd, announced the launch of novel omeprazole orally disintegrating tablet omeprazole OD, omeprazole OD mouth dissolving tablet approved by the U.S. FDA with MelTech melt-in-your-mouth technology, which dissolves the tablet without water in the mouth. Ompeprazole OD is an over-the-counter medication for treating heartburn.
Major players operating in the global proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited.